Walleye Capital LLC Makes New $11.11 Million Investment in Tyra Biosciences, Inc. $TYRA

Walleye Capital LLC bought a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the second quarter, Holdings Channel.com reports. The firm bought 347,898 shares of the company’s stock, valued at approximately $11,112,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TYRA. Tema ETFs LLC bought a new position in shares of Tyra Biosciences in the second quarter valued at approximately $943,000. Seven Fleet Capital Management LP lifted its holdings in Tyra Biosciences by 149.6% during the first quarter. Seven Fleet Capital Management LP now owns 198,585 shares of the company’s stock worth $7,606,000 after acquiring an additional 119,025 shares during the period. Bank of America Corp DE lifted its holdings in Tyra Biosciences by 448.0% during the first quarter. Bank of America Corp DE now owns 209,922 shares of the company’s stock worth $8,040,000 after acquiring an additional 171,612 shares during the period. Janus Henderson Group PLC boosted its position in Tyra Biosciences by 32.5% in the first quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock worth $148,867,000 after purchasing an additional 955,147 shares during the last quarter. Finally, Arkadios Wealth Advisors purchased a new position in Tyra Biosciences in the first quarter worth $1,822,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Trading Up 1.1%

Tyra Biosciences stock opened at $25.29 on Friday. Tyra Biosciences, Inc. has a 12 month low of $9.96 and a 12 month high of $40.65. The business’s 50 day simple moving average is $29.75 and its 200 day simple moving average is $32.50. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -10.54 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. JonesTrading began coverage on Tyra Biosciences in a research note on Wednesday, June 17th. They issued a “buy” rating and a $56.00 price objective for the company. Wolfe Research began coverage on Tyra Biosciences in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $42.00 price target on shares of Tyra Biosciences in a report on Wednesday, August 5th. Bank of America increased their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $46.90.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.